Chen Chien-Li, Pan Tzu-Ming
Department of Biochemical Science and Technology, College of Life Science, National Taiwan University, Taipei, Taiwan.
J Food Drug Anal. 2015 Dec;23(4):719-728. doi: 10.1016/j.jfda.2015.04.013. Epub 2015 Jul 21.
The prevalence of type 2 diabetes mellitus is increasing rapidly, and its treatment with pioglitazone is likely to induce rhabdomyolysis. We aimed to determine the effect of cotreatment with pioglitazone and red mold dioscorea (RMD) produced by Monascus purpureus NTU 568 on pancreas function in streptozotocin (STZ)-induced diabetic rats. In diabetic rats fed RMD, RMD with pioglitazone, and pioglitazone alone, insulin concentrations increased significantly by 18.6-40.4%, 64.0-100.0%, and 52.8%, respectively, compared with that in the diabetic group (p < 0.05). Oral glucose tolerance was impaired in the STZ-induced diabetic group within 4 weeks, however, oral glucose tolerance in rats treated with RMD or RMD with pioglitazone improved after 4 weeks, 6 weeks, and 8 weeks. Findings from this study might lend support to the use of RMD as a novel functional food for the prevention of diabetes.
2型糖尿病的患病率正在迅速上升,用吡格列酮治疗可能会诱发横纹肌溶解症。我们旨在确定用紫红曲霉NTU 568产生的红曲(RMD)与吡格列酮联合治疗对链脲佐菌素(STZ)诱导的糖尿病大鼠胰腺功能的影响。与糖尿病组相比,在喂食RMD的糖尿病大鼠、RMD与吡格列酮联合治疗的大鼠以及单独使用吡格列酮治疗的大鼠中,胰岛素浓度分别显著增加了18.6 - 40.4%、64.0 - 100.0%和52.8%(p < 0.05)。STZ诱导的糖尿病组在4周内口服葡萄糖耐量受损,然而,用RMD或RMD与吡格列酮治疗的大鼠在4周、6周和8周后口服葡萄糖耐量有所改善。本研究结果可能支持将RMD用作预防糖尿病的新型功能性食品。